194 related articles for article (PubMed ID: 27725233)
21. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
22. Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.
Girelli G; Franco P; Sciacero P; Cante D; Borca VC; Pasquino M; Annoscia S; Tofani S; La Porta MR; Ricardi U
Anticancer Res; 2015 Jul; 35(7):4177-82. PubMed ID: 26124375
[TBL] [Abstract][Full Text] [Related]
23. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
25. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908
[TBL] [Abstract][Full Text] [Related]
26. First clinical release of an online, adaptive, aperture-based image-guided radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional rotations of the prostate.
Deutschmann H; Kametriser G; Steininger P; Scherer P; Schöller H; Gaisberger C; Mooslechner M; Mitterlechner B; Weichenberger H; Fastner G; Wurstbauer K; Jeschke S; Forstner R; Sedlmayer F
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1624-32. PubMed ID: 22209149
[TBL] [Abstract][Full Text] [Related]
27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
28. CBCT evaluation of inter- and intra-fraction motions during prostate stereotactic body radiotherapy: a technical note.
Jmour O; Benna M; Champagnol P; Ben Mrad M; Hamrouni A; Obeid L; Lahmamssi C; Bousarsar A; Vial N; Rehailia-Blanchard A; Sotton S; Lan M; Langrand-Escure J; Vallard A; Magné N
Radiat Oncol; 2020 Apr; 15(1):85. PubMed ID: 32307017
[TBL] [Abstract][Full Text] [Related]
29. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy.
Hatiboglu G; Pinkawa M; Vallée JP; Hadaschik B; Hohenfellner M
BJU Int; 2012 Dec; 110(11 Pt B):E647-52. PubMed ID: 22788857
[TBL] [Abstract][Full Text] [Related]
30. EUS-guided fiducial placement before targeted radiation therapy for prostate cancer.
Yang J; Abdel-Wahab M; Ribeiro A
Gastrointest Endosc; 2009 Sep; 70(3):579-83. PubMed ID: 19560140
[TBL] [Abstract][Full Text] [Related]
31. Fiducial markers implantation for prostate image-guided radiotherapy: a report on the transperineal approach.
De Cicco L; Bracelli S
Radiol Med; 2019 Feb; 124(2):132-135. PubMed ID: 30361924
[TBL] [Abstract][Full Text] [Related]
32. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
33. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy.
Susil RC; McNutt TR; DeWeese TL; Song D
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1251-8. PubMed ID: 19939577
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
35. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer.
Pinkawa M; Corral NE; Caffaro M; Piroth MD; Holy R; Djukic V; Otto G; Schoth F; Eble MJ
Radiother Oncol; 2011 Sep; 100(3):436-41. PubMed ID: 21963289
[TBL] [Abstract][Full Text] [Related]
36. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
[TBL] [Abstract][Full Text] [Related]
37. Automatic Substitute Computed Tomography Generation and Contouring for Magnetic Resonance Imaging (MRI)-Alone External Beam Radiation Therapy From Standard MRI Sequences.
Dowling JA; Sun J; Pichler P; Rivest-Hénault D; Ghose S; Richardson H; Wratten C; Martin J; Arm J; Best L; Chandra SS; Fripp J; Menk FW; Greer PB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1144-53. PubMed ID: 26581150
[TBL] [Abstract][Full Text] [Related]
38. Fiducial marker implantation in prostate radiation therapy: complication rates and technique.
Fawaz ZS; Yassa M; Nguyen DH; Vavassis P
Cancer Radiother; 2014 Dec; 18(8):736-9. PubMed ID: 25451675
[TBL] [Abstract][Full Text] [Related]
39. BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.
Pasquier D; Bogart E; Bonodeau F; Lacornerie T; Lartigau E; Latorzeff I
BMC Cancer; 2018 May; 18(1):566. PubMed ID: 29769060
[TBL] [Abstract][Full Text] [Related]
40. Prostate deformation during hypofractionated radiotherapy: an analysis of implanted fiducial marker displacement.
Knybel L; Cvek J; Blazek T; Binarova A; Parackova T; Resova K
Radiat Oncol; 2021 Dec; 16(1):235. PubMed ID: 34876173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
